SEC Comment Letter 0000000000-26-003376 to PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC.
Date: April 2, 2026 · CIK: 0001746473 · Accession: 0000000000-26-003376
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294737
Letter
Re: Pliant Therapeutics, Inc. Registration Statement on Form S-3 Filed March 30, 2026 File No. 333-294737 Dear Bernard Coulie:
April 2, 2026
Bernard Coulie Chief Executive Officer Pliant Therapeutics, Inc. 331 Oyster Point Boulevard South San Francisco, CA 94080
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Marianne Sarrazin, Esq.
Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
April 2, 2026
Bernard Coulie
Chief Executive Officer
Pliant Therapeutics, Inc.
331 Oyster Point Boulevard
South San Francisco, CA 94080
Re: Pliant Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 30, 2026
File No. 333-294737
Dear Bernard Coulie:
This is to advise you that we have not reviewed and will not review your
registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Marianne Sarrazin, Esq.
</TEXT>
</DOCUMENT>